Bharat Biotech Launches Next Generation Oral Cholera Vaccine HILLCHOL®

Bharat Biotech Launches Next Generation Oral Cholera Vaccine HILLCHOL®

Bharat Biotech International Limited (BBIL) announced the launch of HILLCHOL® (BBV131), a novel single-strain Oral Cholera Vaccine (OCV). HILLCHOL® was developed by Bharat Biotech under license from Hilleman Laboratories (funded by Merck, USA and Wellcome Trust, UK), to combat cholera, a significant advancement in global health.

Please click here for more info on Vaccine on Cholera from Bharat BioTech